Paysign (PAYS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual meeting scheduled for May 8, 2026, to elect seven directors and ratify Baker Tilly US, LLP as independent auditor for 2026.
Proxy materials and annual report for 2025 made available online; voting encouraged via internet, mail, or in person.
Record date for voting is March 9, 2026, with 55,185,394 shares outstanding; quorum requires over 50% of shares.
Directors and executive officers control 21.6% of voting shares.
Voting matters and shareholder proposals
Shareholders will vote on electing seven director nominees and ratifying Baker Tilly US, LLP as auditor.
Board recommends voting FOR all director nominees and auditor ratification.
Shareholder proposals for the 2027 meeting must be submitted by November 30, 2026, for inclusion in proxy materials.
Voting results will be reported on Form 8-K within four business days after the meeting.
Board of directors and corporate governance
Board consists of seven members; four are independent per Nasdaq standards.
CEO also serves as Chairman; Board believes this structure aligns strategy and accountability.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.
Board and committees met regularly in 2025; all directors attended at least 75% of meetings.
Code of Ethics and Insider Trading Policy in place; annual questionnaires required for conflict disclosure.
Latest events from Paysign
- Annual meeting to elect seven directors and ratify auditor set for May 8, 2026.PAYS
Proxy filing26 Mar 2026 - 2025 saw 40.5% revenue growth and margin expansion, with 2026 guidance projecting 30–35% growth.PAYS
Q4 202524 Mar 2026 - Rapid growth in patient affordability and tech-driven margin expansion offset plasma headwinds.PAYS
The MicroCap Rodeo Conference - NYC3 Feb 2026 - Strong revenue growth and market expansion in healthcare-focused prepaid payment solutions.PAYS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 30% year-over-year, net income positive, and 2024 guidance raised.PAYS
Q2 20242 Feb 2026 - Patient affordability business is rapidly scaling, driving strong growth and margin expansion.PAYS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 2024 revenue up 23%, pharma patient affordability revenue up 219% year-over-year.PAYS
Q3 202416 Jan 2026 - 2024 revenue up 23.5%, patient affordability soared 214.5%, 2025 outlook strong.PAYS
Q4 202425 Dec 2025 - Board recommends triennial say-on-pay, all directors up for election, and auditor ratification.PAYS
Proxy Filing1 Dec 2025